Advertisement

Journal of Neural Transmission

, Volume 123, Issue 4, pp 431–438 | Cite as

MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study

  • Roberta BiundoEmail author
  • L. Weis
  • S. Bostantjopoulou
  • E. Stefanova
  • C. Falup-Pecurariu
  • M. G. Kramberger
  • G. J. Geurtsen
  • A. Antonini
  • D. Weintraub
  • D. Aarsland
Neurology and Preclinical Neurological Studies - Original Article

Abstract

The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are the most commonly used scales to test cognitive impairment in Lewy body disease (LBD), but there is no consensus on which is best suited to assess cognition in clinical practice and most sensitive to cognitive decline. Retrospective cohort study of 265 LBD patients [Parkinson’s disease (PD) without dementia (PDnD, N = 197), PD with dementia (PDD, N = 40), and dementia with Lewy bodies (DLB, N = 28)] from an international consortium who completed both the MMSE and MoCA at baseline and 1-year follow-up (N = 153). Percentage of relative standard deviation (RSD%) at baseline was the measure of inter-individual variance, and estimation of change (Cohen’s d) over time was calculated. RSD% for the MoCA (21 %) was greater than for the MMSE (13 %) (p = 0.03) in the whole group. This difference was significant only in PDnD (11 vs. 5 %, p < 0.01), but not in PDD (30 vs. 19 %, p = 0.37) or DLB (15 vs. 14 %, p = 0.78). In contrast, the 1-year estimation of change did not differ between the two tests in any of the groups (Cohen’s effect <0.20 in each group). MMSE and MoCA are equal in measuring the rate of cognitive changes over time in LBD. However, in PDnD, the MoCA is a better measure of cognitive status as it lacks both ceiling and floor effects.

Keywords

Parkinson disease MMSE MoCA Dementia with Lewy bodies Rate of cognitive decline 

Notes

Acknowledgments

We are thankful to Pablo Martinez-Martin for helping with statistical analysis

Compliance with ethical standards

All authors gave final approval of this version of the manuscript to be published. We can assure that there is no one else who fulfils the criteria but has not been included as an author.

Funding

This working group is funded by the Research Council of Norway, Norway under the aegis of JPND.

Conflict of interest

The authors have no competing interest to declare.

Supplementary material

702_2016_1517_MOESM1_ESM.doc (169 kb)
Supplementary material 1 (DOC 169 kb)

References

  1. Aarsland D, Andersen K, Larsen JP, Perry R, Wentzel-Larsen T, Lolk A, Kragh-Sorensen P (2004) The rate of cognitive decline in Parkinson disease. Arch Neurol 61:1906–1911CrossRefPubMedGoogle Scholar
  2. Aarsland D, Beyer MK, Kurz MW (2008) Dementia in Parkinson’s disease. Curr Opin Neurol 21:676–682CrossRefPubMedGoogle Scholar
  3. Aarsland D, Muniz G, Matthews F (2011a) Nonlinear decline of mini-mental state examination in Parkinson’s disease. Mov Disord 26:334–337CrossRefPubMedGoogle Scholar
  4. Aarsland D, Muniz G, Matthews F (2011b) Nonlinear decline of mini-mental state examination in Parkinson’s disease. Mov Disord 26:334–337CrossRefPubMedGoogle Scholar
  5. Biundo R, Weis L, Facchini S, Formento-Dojot P, Vallelunga A, Pilleri M, Antonini A (2014) Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. Parkinsonism Relat Disord 20:394–399CrossRefPubMedGoogle Scholar
  6. Bland JM, Altman DG (1995) Comparing two methods of clinical measurement: a personal history. Int J Epidemiol 24(Suppl 1):S7–S14CrossRefPubMedGoogle Scholar
  7. Breitve MH, Chwiszczuk LJ, Hynninen MJ, Rongve A, Bronnick K, Janvin C, Aarsland D (2014) A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer’s disease. Alzheimers Res Ther 6:53-014-0053-6 (eCollection 2014)Google Scholar
  8. Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Troster AI, Uc EY, Parkinson Study Group Cognitive/Psychiatric Working Group (2010) A recommended scale for cognitive screening in clinical trials of Parkinson’s disease. Mov Disord 25:2501–2507CrossRefPubMedPubMedCentralGoogle Scholar
  9. Chou KL, Lenhart A, Koeppe RA, Bohnen NI (2014) Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. Parkinsonism Relat Disord 20:1076–1080CrossRefPubMedPubMedCentralGoogle Scholar
  10. Cohen J (1988) Statistical power analysis for the behavioral sciences. L. Erlbaum Associates, HillsdaleGoogle Scholar
  11. Dalrymple-Alford JC, Livingston L, MacAskill MR, Graham C, Melzer TR, Porter RJ, Watts R, Anderson TJ (2011) Characterizing mild cognitive impairment in Parkinson’s disease. Mov Disord 26:629–636CrossRefPubMedGoogle Scholar
  12. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324CrossRefPubMedGoogle Scholar
  13. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMedGoogle Scholar
  14. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39CrossRefPubMedGoogle Scholar
  15. Gill DJ, Freshman A, Blender JA, Ravina B (2008) The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson’s disease. Mov Disord 23:1043–1046CrossRefPubMedGoogle Scholar
  16. Glatt SL, Hubble JP, Lyons K, Paolo A, Troster AI, Hassanein RE, Koller WC (1996) Risk factors for dementia in Parkinson’s disease: effect of education. Neuroepidemiology 15:20–25CrossRefPubMedGoogle Scholar
  17. Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, Weintraub D (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73:1738–1745CrossRefPubMedPubMedCentralGoogle Scholar
  18. Hu MT, Szewczyk-Krolikowski K, Tomlinson P, Nithi K, Rolinski M, Murray C, Talbot K, Ebmeier KP, Mackay CE, Ben-Shlomo Y (2014) Predictors of cognitive impairment in an early stage Parkinson’s disease cohort. Mov Disord 29:351–359CrossRefPubMedPubMedCentralGoogle Scholar
  19. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, Spokes EG (2000) A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 54:1596–1602CrossRefPubMedGoogle Scholar
  20. Kandiah N, Zhang A, Cenina AR, Au WL, Nadkarni N, Tan LC (2014) Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson’s disease. Parkinsonism Relat Disord 20:1145–1148CrossRefPubMedGoogle Scholar
  21. Kelley K (2007) Sample size planning for the coefficient of variation from the accuracy in parameter estimation approach. Behav Res Methods 39:755–766CrossRefPubMedGoogle Scholar
  22. Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA (2010) Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis 19:1401–1408PubMedGoogle Scholar
  23. Lessig S, Nie D, Xu R, Corey-Bloom J (2012a) Changes on brief cognitive instruments over time in Parkinson’s disease. Mov Disord 27:1125–1128CrossRefPubMedGoogle Scholar
  24. Lessig S, Nie D, Xu R, Corey-Bloom J (2012b) Changes on brief cognitive instruments over time in Parkinson’s disease. Mov Disord 27:1125–1128CrossRefPubMedGoogle Scholar
  25. Levy G, Schupf N, Tang MX, Cote LJ, Louis ED, Mejia H, Stern Y, Marder K (2002) Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 51:722–729CrossRefPubMedGoogle Scholar
  26. Malek-Ahmadi M, Powell JJ, Belden CM, O’Connor K, Evans L, Coon DW, Nieri W (2015) Age- and education-adjusted normative data for the Montreal Cognitive Assessment (MoCA) in older adults age 70–99. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 22:755–761CrossRefPubMedGoogle Scholar
  27. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M, Consortium on DLB (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872CrossRefPubMedGoogle Scholar
  28. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699CrossRefPubMedGoogle Scholar
  29. Nelson PT, Jicha GA, Kryscio RJ, Abner EL, Schmitt FA, Cooper G, Xu LO, Smith CD, Markesbery WR (2010) Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 257:359–366CrossRefPubMedPubMedCentralGoogle Scholar
  30. Oesterhus R, Soennesyn H, Rongve A, Ballard C, Aarsland D, Vossius C (2014) Long-term mortality in a cohort of home-dwelling elderly with mild Alzheimer’s disease and Lewy body dementia. Dement Geriatr Cogn Disord 38:161–169CrossRefPubMedGoogle Scholar
  31. Owen AM (2004) Cognitive dysfunction in Parkinson’s disease: the role of frontostriatal circuitry. Neuroscientist 10:525–537CrossRefPubMedGoogle Scholar
  32. Richardson JTE (2011) The analysis of 2 × 2 contingency tables—Yet again. Stat Med 30:890CrossRefPubMedGoogle Scholar
  33. Rongve A, Vossius C, Nore S, Testad I, Aarsland D (2014) Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer’s dementia. Int J Geriatr Psychiatry 29:392–398CrossRefPubMedGoogle Scholar
  34. Santangelo G, Siciliano M, Pedone R, Vitale C, Falco F, Bisogno R, Siano P, Barone P, Grossi D, Santangelo F, Trojano L (2015) Normative data for the Montreal Cognitive Assessment in an Italian population sample. Neurol Sci 36:585–591CrossRefPubMedGoogle Scholar
  35. Temlett JA, Thompson PD (2006) Reasons for admission to hospital for Parkinson’s disease. Intern Med J 36:524–526CrossRefPubMedGoogle Scholar
  36. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653CrossRefPubMedGoogle Scholar
  37. van Steenoven I, Aarsland D, Hurtig H, Chen-Plotkin A, Duda JE, Rick J, Chahine LM, Dahodwala N, Trojanowski JQ, Roalf DR, Moberg PJ, Weintraub D (2014) Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale-2 scores in Parkinson’s disease. Mov Disord 29:1809–1815CrossRefPubMedPubMedCentralGoogle Scholar
  38. Verghese J, Crystal HA, Dickson DW, Lipton RB (1999) Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 53:1974–1982CrossRefPubMedGoogle Scholar
  39. Wang CS, Pai MC, Chen PL, Hou NT, Chien PF, Huang YC (2013) Montreal Cognitive Assessment and Mini-Mental State Examination performance in patients with mild-to-moderate dementia with Lewy bodies, Alzheimer’s disease, and normal participants in Taiwan. Int Psychogeriatr 25:1839–1848CrossRefPubMedGoogle Scholar
  40. Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, Wang C, Tan MS, Tan L (2015) Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 86:135–143CrossRefPubMedGoogle Scholar
  41. Zadikoff C, Fox SH, Tang-Wai DF, Thomsen T, de Bie RM, Wadia P, Miyasaki J, Duff-Canning S, Lang AE, Marras C (2008) A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson’s disease. Mov Disord 23:297–299CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2016

Authors and Affiliations

  • Roberta Biundo
    • 1
    Email author
  • L. Weis
    • 1
  • S. Bostantjopoulou
    • 2
  • E. Stefanova
    • 3
  • C. Falup-Pecurariu
    • 4
  • M. G. Kramberger
    • 5
  • G. J. Geurtsen
    • 6
  • A. Antonini
    • 1
  • D. Weintraub
    • 7
  • D. Aarsland
    • 8
    • 9
  1. 1.Parkinson’s Disease and Movement Disorders Unit“Fondazione Ospedale San Camillo” - I.R.C.C.S.Venice-LidoItaly
  2. 2.3rd Department of NeurologyAristotle University of ThessalonikiThessaloníkiGreece
  3. 3.Clinic of Neurology CCS, School of MedicineUniversity of BelgradeBelgradeSerbia
  4. 4.Department of Neurology, Faculty of Medicine, County Emergency Clinic HospitalTransilvania UniversityBrasovRomania
  5. 5.Department of NeurologyUniversity Medical Center LjubljanaLjubljanaSlovenia
  6. 6.Department of Medical PsychologyAcademic Medical HospitalAmsterdamThe Netherlands
  7. 7.Department of PsychiatryUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  8. 8.Department of NVS, Center for Alzheimer ResearchKarolinska InstituteStockholmSweden
  9. 9.Centre for Age-Related MedicineStavanger University HospitalStavangerNorway

Personalised recommendations